For the Inventor, By the Inventor

Enter assignee name

Thousand Oaks, CA, United States of America

Amgen Inc.

USPTO Granted Patents = 1,975

CIPO Patents = 59

EPO Patents = 596

Trademarks = 100

Forward Citations = 24,516

Loading Chart...

Loading Chart...

2,212 inventors (with patents filed for the assignee):

Ning Chen (55 out of 55 patents)

Thomas Charles Boone (53 out of 54 patents)

Scott Robert Gibson (50 out of 86 patents)

4. Jennifer Rebecca Allen (49 out of 50 patents)

5. Mark Henry Norman (46 out of 51 patents)

6. Jonathan B Houze (45 out of 56 patents)

7. Patricia Lopez (43 out of 43 patents)

8. Andrew Stewart Tasker (43 out of 66 patents)

9. Qingyian Liu (41 out of 41 patents)

10. Thomas T Nguyen (40 out of 43 patents)

11. Julio Cesar Medina (40 out of 73 patents)

12. Chadwick Terence King (39 out of 59 patents)

13. Nobuko Nishimura (39 out of 39 patents)

14. Robert Michael Rzasa (38 out of 38 patents)

15. Jian Jeffrey Chen (38 out of 62 patents)

Core Competencies:

Drug Delivery Devices

Heterocyclic Compounds

KRAS G12C Inhibitors

Antibody Constructs

Metabolic Disorders

Aqueous Antibody Formulation

KIF18A Inhibitors

Autoinjector

Mass Spectrometric Analysis

Closed System Transfer Device

Formulations of Apremilast

Proximity Sensor Technology

1,975 patents: Sort by Forward Citations

1. 12509442 - KIF18A inhibitors (2025-12-30),

2. 12503700 - Control of total afucosylated glycoforms of antibodies produced in cell culture (2025-12-23),

3. D1106445 - Handheld drug delivery device (2025-12-16),

4. 12497666 - Nucleic acid biomarker and use thereof (2025-12-16),

5. 12493943 - Apparatuses, systems and methods for plunger-stopper depth measurement in pre-filled syringes (2025-12-09),

6. 12485219 - Drug delivery devices with partial drug delivery member retraction (2025-12-02),

7. 12480858 - Automated visual inspection (2025-11-25),

8. 12473329 - Methods directed to crystalline biomolecules (2025-11-18),

9. 12473289 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use (2025-11-18),

10. 12473281 - Synthesis of KRAS G12C inhibitor compound (2025-11-18),

11. 12466825 - Synthesis of KRAS G12C inhibitor compound (2025-11-11),

12. 12465652 - Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins (2025-11-11),

13. D1101191 - Vial sleeve (2025-11-04),

14. 12459932 - KIF18A inhibitors (2025-11-04),

15. 12459896 - Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile (2025-11-04),

Amgen Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines to treat serious illnesses. With a commitment to cutting-edge research and a dedication to improving patient outcomes, Amgen has become a global leader in biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

1,975 Patents

#1 in Thousand Oaks, CA

#59 in California

#247 in US

#495 in the World

Thousand Oaks, CA, United States of America

Amgen Inc.

Forward Citations = 24,516

2,212 inventors:

Ning Chen (55 out of 55 patents)

Thomas Charles Boone (53 out of 54 patents)

Scott Robert Gibson (50 out of 86 patents)

4. Jennifer Rebecca Allen (49 out of 50 patents)

5. Mark Henry Norman (46 out of 51 patents)

Please report any incorrect information to support@idiyas.com

Loading…